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BACKGROUND: Primary outcomes analysis of the Multicenter Study of MagLev Technology in Patients
Undergoing MCS Therapy With HeartMate 3 (MOMENTUM 3) trial short-term cohort demonstrated a
higher survival rate free of debilitating stroke and reoperation to replace/remove the device (primary end-
point) in patients receiving the HeartMate 3 (HM3) compared with the HeartMate (HMII). In this study
we sought to evaluate the individual and interactive effects of pre-speciﬁed patient subgroups (age, sex,
race, therapeutic intent [bridge to transplant/bridge to candidacy/destination therapy] and severity of
illness) on primary end-point outcomes in MOMENTUM 3 patients implanted with HM3 and HMII
devices.
METHODS: Cox proportional hazard models were used to analyze patients enrolled in the “as-treated cohort”
(n ¼ 289) of the MOMENTUM 3 trial to: (1) determine interaction of various subgroups on primary end-
point outcomes; and (2) identify independent variables associated with primary end-point success.
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RESULTS: Baseline characteristics were well balanced among HM3 (n ¼ 151) and HMII (n ¼ 138)
cohorts. No signiﬁcant interaction between the sub-groups on primary end-point outcomes was observed.
Cox multivariable modeling identiﬁed age (≤65 years vs465 years, hazard ratio 0.42 [95% conﬁdence
interval 0.22 to 0.78], p ¼ 0.006]) and pump type (HM3 vs HMII, hazard ratio 0.53 [95% conﬁdence
interval 0.30 to 0.96], p ¼ 0.034) to be independent predictors of primary outcomes success. After
adjusting for age, no signiﬁcant impact of sex, race, therapeutic intent and INTERMACS proﬁles on
primary outcomes were observed.
CONCLUSIONS: This analysis of MOMENTUM 3 suggests that younger age (≤65 years) at implant and
pump choice are associated with a greater likelihood of primary end-point success. These ﬁndings further
suggest that characterization of therapeutic intent into discrete bridge-to-transplant and destination therapy
categories offers no clear clinical advantage, and should ideally be abandoned.
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The HeartMate 3 left ventricular assist system (HM3
LVAS), an intrathoracic centrifugal continuous-ﬂow pump,
has been introduced for the treatment of advanced heart
failure and is uniquely engineered to enhance hemocompat-
ibility of the blood–device interface.1–3 In a 6-month
analysis of the largest comparative effectiveness trial of
LVAS to date (i.e., the Multicenter Study of MagLev
Technology in Patients Undergoing Mechanical Circulatory
Support Therapy With HeartMate 3 [MOMENTUM 3]), the
HM3 was shown to be superior to the HeartMate II (HMII)
LVAS in achieving the primary end-point of survival
freedom from disabling stroke or reoperation to replace the
device.3 The superiority was largely deﬁned by the absence
of suspected or established pump thrombosis in this short-
term analysis. Further scrutiny is required to determine
whether the principal outcomes observed are similarly noted
across various demographic and clinical subgroups.
Among others, there are 5 fundamental sub-groups of
interest in determining LVAS outcomes, including age, sex,
race, therapeutic intent (bridge to transplant [BTT] or
destination therapy [DT]) and disease severity, as adjudi-
cated by the INTERMACS (Interagency Registry for
Mechanically Assisted Circulatory Support) clinical pro-
ﬁles. Age has been the best studied risk factor and has been
shown to be a strong predictor of adverse outcome,4,5 but its
importance has been controversial in the literature.6–8
Studies on the impact of sex on current generation LVASs
have suggested a higher risk of neurologic complications in
women, although its conclusive effect on survival has not
been forthcoming.9–14 The inﬂuence of race or ethnicity
has received considerable attention in the general
cardiovascular realm, but the data remain scarce in the
context of mechanical circulatory support.13,15,16 Greater
disease severity (based on INTERMACS proﬁle) and DT as
therapeutic intent have both been associated with a
heightened early hazard for death in the most recent
INTERMACS annual report.17
The primary objectives of this current study were as
follows: (1) to determine whether the primary results from
the MOMENTUM 3 trial were disparately inﬂuenced by
any of the 5 pre-speciﬁed subgroup variables; (2) to deﬁne
differences in the key components of various observed
outcomes within the subgroups; and (3) to evaluate
interactions, if any, between these discrete demographic
and clinical variables.
Methods
MOMENTUM 3 clinical trial
The MOMENTUM 3 trial is a prospective, randomized, multi-
center clinical investigation comparing the HM3 with the HMII
LVAS for the treatment of advanced heart failure in patients
refractory to optimal medical therapy.18 The trial includes 69
participating centers in the United States wherein eligible BTT
and DT LVAS candidates were randomly assigned to receive
either the HM3 or the HMII, with the primary end-point being
survival free of disabling stroke and reoperation to replace
or remove the device, assessed at 6 and 24 months post-
implantation. The trial details have been reported previously.6,18
The short-term cohort includes the ﬁrst 294 patients (with 289
comprising the “as-treated cohort”) of 1,028 enrolled in the full
trial, wherein the primary end-point was powered to demonstrate
non-inferiority of the HM3 to the HMII at 6 months post-
implantation.
Subgroup analysis
The MOMENTUM 3 clinical trial protocol pre-speciﬁed an
analysis of 5 patient subgroups stratiﬁed by age, sex, race,
therapeutic intent (BTT/DT) and severity of illness (INTERMACS
proﬁles). Age was analyzed as a continuous variable as well as a
categorical variable dichotomized at a cut-off age of 65 years. This
cut-off is commonly used by transplant programs as the age limit
for transplant candidacy, and to make pivotal decisions regarding
the therapeutic intent of device implantation as (BTT or DT).
The patients in this secondary pre-speciﬁed analysis included the
289 patients implanted with the HM3 and HMII LVAS in the
“as-treated” population within the MOMENTUM 3 short-term
cohort (Figure 1).
Statistical analysis
Continuous variables are depicted as mean ± standard deviation or
median (range), and categorical variables are depicted as percent.
Comparison of continuous data between groups was performed
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using Wilcoxon’s rank sum test. Comparison of categorical data
between groups was performed using Fisher’s exact test. The time-
to-event analysis was performed using the Kaplan–Meier method.
Two speciﬁc analyses were performed using Cox proportional-
hazard models in order to:
1. Compare primary end-point (survival free of disabling stroke
and reoperation to remove or replace the device) outcomes
between HM3 and HMII within each of the 5 pre-speciﬁed
subgroups and to test for signiﬁcant interactions that may exist
between the pre-speciﬁed subgroups.
2. Determine independent predictors of primary end-point success
in the combined “as-treated” cohort of both HM3 and HMII
patients. Pump type and the 5 pre-speciﬁed subgroups were
entered simultaneously as covariates into the multivariable
model. This approach was also utilized to evaluate the
relationship between age (as continuous variable), pump type
and the other 4 pre-speciﬁed subgroups (therapeutic intent, sex,
INTERMACS proﬁle and race) on primary end-point outcomes
in the combined cohort. Two-sided p o 0.05 was considered
signiﬁcant.
Lastly, an analysis comparing baseline characteristics and
adverse events was performed in the patient subgroups identiﬁed as
having statistically signiﬁcant independent predictors of primary
end-point outcomes. All events occurring within 6 months post-




Two hundred eighty-nine patients (151 with HM3, 138 with
HMII) formed the “as-treated” cohort for this analysis.
Baseline characteristics are depicted in Table 1. More than
85% of the patients in both cohorts were receiving
intravenous inotropic support and 410% were on an
intra-aortic balloon pump at the time of randomization.
The majority of patients were classiﬁed as INTERMACS
Proﬁle 2 or 3, and a majority of the patients in both groups
were implanted with DT as the therapeutic intent.
Primary end-point
A total of 49 patients in the “as-treated” cohort failed the
primary end-point. Table S1 (refer to Supplementary
Material online at www.jhltonline.org/) depicts the ﬁrst
event that contributed to primary end-point failure and the
total number of disabling strokes, reoperations for device
malfunction and deaths for HM3 and HMII patients.
Analysis 1: Comparison of outcomes (HM3 vs HMII)
within patient subgroups
Figure 2 depicts comparison of hazard ratios and their
interaction p-values for each of the 5 pre-speciﬁed
subgroups. No signiﬁcant interaction in primary end-point
outcomes was observed between patient subgroups.
Analysis 2: Multivariable analysis of primary end-
point outcomes
Figure 3 shows the results of the multivariable analysis of
subgroups impacting primary end-point success in the full
cohort (HMIIþHM3) of patients. All covariates were
entered simultaneously into the Cox proportional hazards
model. Age and device type were the 2 primary independent
predictors of primary end-point success. When device type
and age are accounted for, neither sex, gender, therapeutic
intent nor severity of illness were predictive of primary
outcome success. Furthermore, when age was analyzed as a
continuous variable, the HM3 retained a lower estimated
risk of primary end-point failure compared with the HMII
over the entire age range of patients of 20 to 80 years
(Figure 4). A similar analysis of primary end-point
outcomes as a function of age, but stratiﬁed by therapeutic
Figure 1 Study cohort.
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intent, level of illness, sex and race for both HM3 and HMII,
are shown in Figure 5A–D. There were minimal differences
in outcomes between these subgroups over the entire age
range for both the HM3 and HMII patient cohorts.
Analysis 3: Differences in patient characteristics and
outcomes stratiﬁed by age
Because age was found to be a strong predictor of outcomes,
additional analyses were performed comparing baseline
characteristics and adverse events between older (age 465
years) and younger (age ≤65 years) patients. Tables 2 and 3
depict differences in baseline characteristics and all major
adverse events for the combined cohort of HM3 and HMII
patients. Older patients were more often Caucasian, had an
ischemic etiology of heart failure, had worse baseline
renal function, and were more likely to have received LVAS
as DT. Moreover, older patients were more likely to have a
bleeding event, particularly in the gastrointestinal tract, have
a higher incidence of disabling stroke, and were more likely
to develop renal failure. On the other hand, the incidence of
right heart failure, infection and suspected pump thrombosis
was not different between groups.
Discussion
The 3 main ﬁndings of our study are as follows: First, the
superiority of the HM3 device over the HMII pump for the
primary outcome end-point, as noted in the MOMENTUM
3 trial publication, is not due to a performance bias within any
single one the 5 pre-speciﬁed subgroups associated with age,
sex, therapeutic intent or severity of illness.3 Second, in
multivariate analyses incorporating the 5 pre-speciﬁed variables
and pump type, only HM3 LVAS and younger age (o65 years)
emerged as independent predictors of primary end-point success.
Third, when age at device implant was examined in combination
with the other pre-speciﬁed variables, no discernible changes in
achieving primary end-point success were noted.
The impact of age on outcomes after LVAS implantation
has received considerable attention in the literature. Sandner
and colleagues retrospectively reviewed their institutional
experience with 3 different continuous-ﬂow LVASs as BTT.
Age 460 years emerged as the only independent predictor
of post-LVAS death. Moreover, the older cohort had a lower
incidence of successful bridging and a greater likelihood of
post-operative renal failure. Interestingly, however, post-
transplantation survival up to 5 years was similar.5 Lushaj
et al dichotomized their 128 LVAS recipients (all but
1 received the HMII pump) into those o65 and465 years
of age. The older cohort had a statistically higher incidence
of post-operative cerebrovascular accident but similar
survival at 2 years.4 Kim et al6 and Huang et al7 both
demonstrated a lack of impact of age on LVAS outcomes;
however, one of these studies was an observational registry-
type study that included highly experienced centers,
whereas the other investigation involved an earlier gen-
eration device analysis of the now-decommissioned Nova-
cor pump. A more contemporary study by Cowger and
colleagues with the HMII LVAS demonstrated advancing
age as a signiﬁcant risk marker for poor outcome.19
Similarly, our results conﬁrm this association independent
of device type and suggest that age 465 years portends a
worse outcome post-LVAS, irrespective of device choice.






Age (years) 64 (19 to 81) 61 (24 to 78)
Male sex 120 (79) 111 (80)
Race
White 103 (68) 105 (76)
Black 37 (25) 23 (17)
Othera 11 (7) 10 (7)
Body surface area (m2) 2.1 ± 0.3 2.1 ± 0.3
Ischemic cause of heart failure 68 (45) 68 (49)
History of stroke 12 (8) 14 (10)
Concomitant medication or
intervention
Intravenous inotropic agents 131 (87) 118 (86)
Diureticsb 133 (88) 133 (96)
ACE inhibitor 37 (25) 37 (27)
Angiotensin II receptor
antagonist
10 (7) 18 (13)
β-blocker 91 (60) 77 (56)
CRT/CRT-D 59 (39) 50 (36)
ICD/CRT-D 100 (66) 97 (70)
IABP 18 (12) 18 (13)
LVEF (%) 17.1 ± 5.0 17.4 ± 4.9
Arterial blood pressure (mm Hg)
Systolicc 110 ± 16 106 ± 12
Diastolic 67 ± 10 66 ± 10
Mean 81 ± 11 79 ± 10
PCWP (mm Hg) 23 ± 9 22 ± 9
Cardiac index (liters/min/m2) 1.9 ± 0.5 2.0 ± 0.7
PVR (Wood units) 3.2 ± 1.7 3.1 ± 1.6
RAP (mm Hg) 10 ± 6 11 ± 7
Serum sodium (mmol/liter) 135.6 ± 3.9 135.0 ± 4.2
Serum creatinine (mg/ml) 1.4 ± 0.4 1.4 ± 0.4
INTERMACS proﬁle
1 1 (1) 2 (1)
2 50 (33) 43 (31)
3 76 (50) 69 (50)
4 22 (15) 22 (16)
5 to 7d 2 (1) 2 (1)
Intended use of device at implant
Bridge to transplant 40 (26) 36 (26)
Bridge to candidacy 27 (18) 24 (17)
Destination therapy 84 (56) 78 (57)
Data are expressed as median (range), number (%) or mean ±
standard deviation. ACE, angiotensin-converting enzyme; CRT-D,
cardiac resynchronization therapy-deﬁbrillator; IABP, intra-aortic
balloon pump; ICD, implantable cardioverter-deﬁbrillator; INTERMACS,
Interagency Registry for Mechanically Assisted Circulatory Support;
LVEF, left ventricular ejection fraction; PCWP, pulmonary capillary
wedge pressure; PVR, pulmonary vascular resistance; RAP, right atrial
pressure.
aIncludes Asian, Native Hawaiian or Paciﬁc Islanders.
bDiuretic use was statistically signiﬁcant (p ¼ 0.01).
cSystolic blood pressure was statistically signiﬁcant (p = 0.008).
dThere were no subjects with INTERMACS Proﬁles 6 or 7 in either
group.
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Greater consistency in outcomes has been reported when
examining the impact of sex on outcomes after LVAD
implantation. Uniformly, no difference in survival has been
seen between females and males.9–14 A higher incidence of
neurologic complications, however, has been reported by
some investigators,9–11 but not others.12–14 In the present
study, and in support of the aforementioned studies, gender
had no impact in primary end-point outcomes (which included
survival and disabling stroke), even when adjusted for age.
It remains to be seen whether this represents the shorter
duration of follow-up (6 months) or lower rate of events
encountered.
Race has only been meagerly studied in the durable
LVAS realm. Tsiouris and colleagues compared post-LVAS
survival among 32 black and 56 white patients16;
van Meeteren and colleagues assessed survival at up to
5 years in 586 white and 112 black patients13; and Aggarwal
et al contrasted survival differences between 34 white and
33 black patients.15 Our study has conﬁrmed the observation
that race does not substantially alter or inﬂuence post-
operative LVAS outcomes.
MOMENTUM 3 is the ﬁrst clinical trial to enroll an “all-
comer” population including BTT or DT, thus allowing for
a comparative assessment of clinical outcomes between
contemporaneous enrollees. Until now, most registry
analyses suggest a gradient of outcome between BTT and
DT patients such that event-free survival is lower in those
receiving LVAS with a lifelong intent.17,20 Uniquely, our
analysis has demonstrated that outcomes are not disparately
inﬂuenced by therapeutic intent alone, at least with regard to
the use of the HM3 LVAS. The key variable inﬂuencing
outcome is that of age and not the artiﬁcial boundaries
created by therapeutic intent, which often are dynamic and
change over time. These ﬁndings once again support the
notion that use of such discrimination in discrete categories
is unwise clinically and an LVAS should be used as
a “therapeutic strategy in the journey of disease pro-
gression.”21
As one would surmise, INTERMACS score as a measure
of severity of illness has been shown to correlate with
Figure 2 Hazard ratios for event-free survival in the pre-speciﬁed subgroups. Hazard ratios (HRs) are presented for HM3 vs HMII.
Figure 3 Multivariable analysis of impact of subgroups on
primary end-point success.
Figure 4 Estimated risk of primary end-point failure in HM3
and HMII patients over the age range of 20 to 80 years.
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outcomes with patients with higher acuity of illness
(INTERMACS Proﬁles 1 or 2) faring worse after durable
LVAS implantation. MOMENTUM 3 includes a distribution
of patients with an INTERMACS proﬁle that is quite typical
for those implanted with current generation LVASs, as the
majority of patients were in the higher acuity group (85% in
Figure 5 Estimated risk of primary end-point failure in HM3 and HMII patients over the age range of 20 to 80 years, stratiﬁed by:
(A) gender; (B) race; (C) therapeutic intent; and (D) INTERMACS proﬁle.
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INTERMACS Proﬁles 1, 2 or 3). The recent INTERMACS
annual report gathered from420,000 pump implants showed
a 55% and 37% increase in early mortality for INTERMACS
Proﬁles 1 and 2, respectively.17 We did not ﬁnd that
INTERMACS level was independently predictive of primary
end-point outcome; however, as would be expected in a
clinical trial with strict inclusion criteria, we did not enroll
sufﬁcient patients in the “crash-and-burn” cardiogenic shock
(INTERMACS Proﬁle 1) category.
As with any investigation, there are limitations to our
analyses. First and foremost, this investigation represents an
early experience with the HM3 device, as the trial represents
the ﬁrst use of this new LVAS in the United States. Second,
the analysis was limited to a small cohort of enrollees with
follow-up to only 6 months. A longer duration of follow-up
and greater number of enrollees will be needed to assess the
effects of the various subgroups on individual components
of clinical outcome, particularly all-cause survival. This will
require a further re-examination of this issue once the larger
trial experience is available. Also, with only 49 patients
experiencing a primary end-point failure event, simulta-
neous inclusion of all 5 subgroup variables and device type
into the multivariable analysis may have led to overﬁtting of
the model.






Male sex 147 (83) 84 (76)
White racea 118 (66) 90 (81)
Ischemic cause of heart failureb 75 (42) 61 (55)
LVEF 17.0 ± 5.2 17.6 ± 4.5
PCWP (mm Hg) 23 ± 9 22 ± 9
Cardiac index (liters/min/m2) 1.9 ± 0.6 2.0 ± 0.6
RAP (mm Hg) 11 ± 7 10 ± 5
Serum creatinine (mg/ml)c 1.3 ± 0.4 1.5 ± 0.4
INTERMACS proﬁle
1 3 (2) 0 (0)
2 56 (31) 37 (33)
3 92 (52) 53 (48)
4 25 (14) 19 (17)
5 to 7 2 (1) 2 (2)
Therapeutic intentd
Bridge to transplant 63 (35) 13 (12)
Bridge to candidacy 39 (22) 12 (11)
Destination therapy 76 (43) 86 (77)
Data are expressed as number (%) or mean ± standard deviation. GI, gastrointestinal; INTERMACS, Interagency Registry for Mechanically Assisted
Circulatory Support; LVEF, left ventricular ejection fraction; PCWP, pulmonary capillary wedge pressure; RAP, right atrial pressure.
aRace (p ¼ 0.02).
bIschemic etiology (p ¼ 0.04).
cSerum creatinine (p o 0.01).
dTherapeutic intent (p o 0.01).
Table 3 Differences in Key Adverse Events: Age ≤65 vs Age 465 Years
Adverse event
Age ≤65 (n ¼ 178) Age 465 (n ¼ 111)
Patients (%) Events Patients (%) Events p
Any bleeding 53 (30%) 90 51 (46%) 105 0.006
GI bleeding 22 (12%) 39 23 (21%) 44 0.07
Any stroke 14 (8%) 16 13 (12%) 13 0.30
Hemorrhagic stroke 6 (3%) 6 6 (5%) 6 0.55
Ischemic stroke 10 (6%) 10 7 (6%) 7 0.80
Disabling stroke 5 (3%) 5 9 (8%) 9 0.05
Other neurologic event 10 (6%) 10 7 (6%) 7 0.80
Suspected thrombosis 10 (6%) 12 4 (4%) 6 0.58
Right heart failure 43 (24%) 46 36 (32%) 39 0.14
Renal failure 9 (5%) 10 20 (18%) 20 o0.001
Major Infection 63 (35%) 90 48 (43%) 86 0.21
Drive-line infection 21 (12%) 23 6 (5%) 9 0.10
GI, gastrointestinal.
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In conclusion, this pre-speciﬁed, secondary 6-month
analysis of the MOMENTUM 3 trial has demonstrated that
the observed superiority of the HM3 compared with the
HMII LVAS is not the result of a singular inﬂuence of any
particular pre-speciﬁed subgroup analyzed. We have further
determined that younger age at LVAS implant coupled and
use of the HM3 LVAS are distinctly favorable factors with
regard to primary end-point success. Analysis of the long-
term experience in the trial will be necessary to better deﬁne
the impact of sub-group variables on all-cause survival.
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